BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 28306620)

  • 21. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Initial experience of integrated PET/MR mammography in patients with invasive ductal carcinoma.
    Kong EJ; Chun KA; Bom HS; Lee J; Lee SJ; Cho IH
    Hell J Nucl Med; 2014; 17(3):171-6. PubMed ID: 25397622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Objective and subjective comparison of standard 2-D and fully 3-D reconstructed data on a PET/CT system.
    Strobel K; Rüdy M; Treyer V; Veit-Haibach P; Burger C; Hany TF
    Nucl Med Commun; 2007 Jul; 28(7):555-9. PubMed ID: 17538397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Whole-Body Metabolic Tumor Volume, as Determined by (18)F-FDG PET/CT, as a Prognostic Factor of Outcome for Patients With Breast Cancer Who Have Distant Metastasis.
    Son SH; Lee SW; Jeong SY; Song BI; Chae YS; Ahn BC; Lee J
    AJR Am J Roentgenol; 2015 Oct; 205(4):878-85. PubMed ID: 26204115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Value of true whole-body FDG-PET/CT scanning protocol in oncology: optimization of its use based on primary diagnosis.
    Sebro R; Mari-Aparici C; Hernandez-Pampaloni M
    Acta Radiol; 2013 Jun; 54(5):534-9. PubMed ID: 23463863
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Head and neck cancer: dedicated FDG PET/CT protocol for detection--phantom and initial clinical studies.
    Yamamoto Y; Wong TZ; Turkington TG; Hawk TC; Coleman RE
    Radiology; 2007 Jul; 244(1):263-72. PubMed ID: 17495174
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Respiratory-gated time-of-flight PET/CT during whole-body scan for lung lesions: feasibility in a routine clinical setting and quantitative analysis.
    Suzawa N; Ichikawa Y; Ishida M; Tomita Y; Nakayama R; Sakuma H
    Ann Nucl Med; 2016 Dec; 30(10):722-730. PubMed ID: 27566685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Performance comparison of a dedicated total breast PET system with a clinical whole-body PET system: a simulation study.
    Samanta S; Jiang J; Hamdi M; Register AZ; Majewski S; Williams MB; Turkington TG; Tornai MP; Laforest R; O'Sullivan JA; Tai YC
    Phys Med Biol; 2021 May; 66(11):. PubMed ID: 33892480
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of Optimal Quantification of FDG PET Imaging in the Clinical Practice of Radiology.
    Ziai P; Hayeri MR; Salei A; Salavati A; Houshmand S; Alavi A; Teytelboym OM
    Radiographics; 2016; 36(2):481-96. PubMed ID: 26963458
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic performance of CT attenuation values of focal 18F-FDG avid breast lesions detected on whole-body PET-CT in postoperative breast cancer patients.
    Plaza MJ; Collado-Mesa F; Bokhoor J; Alperin N; Yepes MM
    Breast J; 2014; 20(3):235-42. PubMed ID: 24750508
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adrenal lesions: characterization with fused PET/CT image in patients with proved or suspected malignancy--initial experience.
    Blake MA; Slattery JM; Kalra MK; Halpern EF; Fischman AJ; Mueller PR; Boland GW
    Radiology; 2006 Mar; 238(3):970-7. PubMed ID: 16505394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors.
    Gaertner FC; Beer AJ; Souvatzoglou M; Eiber M; Fürst S; Ziegler SI; Brohl F; Schwaiger M; Scheidhauer K
    Invest Radiol; 2013 May; 48(5):263-72. PubMed ID: 23385399
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic accuracy of whole-body diffusion-weighted magnetic resonance imaging with 3.0 T in detection of primary and metastatic neoplasms.
    Akay S; Kocaoglu M; Emer O; Battal B; Arslan N
    J Med Imaging Radiat Oncol; 2013 Jun; 57(3):274-82. PubMed ID: 23721135
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Image Quality and Diagnostic Performance of a Digital PET Prototype in Patients with Oncologic Diseases: Initial Experience and Comparison with Analog PET.
    Nguyen NC; Vercher-Conejero JL; Sattar A; Miller MA; Maniawski PJ; Jordan DW; Muzic RF; Su KH; O'Donnell JK; Faulhaber PF
    J Nucl Med; 2015 Sep; 56(9):1378-85. PubMed ID: 26159588
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of attenuation correction on lesion detectability in FDG PET of breast cancer.
    Bleckmann C; Dose J; Bohuslavizki KH; Buchert R; Klutmann S; Mester J; Jänicke F; Clausen M
    J Nucl Med; 1999 Dec; 40(12):2021-4. PubMed ID: 10616880
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of Positron Emission Tomography Quantification Using Magnetic Resonance- and Computed Tomography-Based Attenuation Correction in Physiological Tissues and Lesions: A Whole-Body Positron Emission Tomography/Magnetic Resonance Study in 66 Patients.
    Seith F; Gatidis S; Schmidt H; Bezrukov I; la Fougère C; Nikolaou K; Pfannenberg C; Schwenzer N
    Invest Radiol; 2016 Jan; 51(1):66-71. PubMed ID: 26348596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contribution of FDG PET/CT for the Optimization of the Management of Additional Lesions Detected on Local Staging Breast MRI.
    Jalaguier-Coudray A; Delarbre B; Brenot-Rossi I; Houvenaeghel G; Villard-Mahjoub R; Viens P; Thomassin-Naggara I
    AJR Am J Roentgenol; 2016 Apr; 206(4):891-900. PubMed ID: 27003055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of whole-body PET/CT, dedicated high-resolution head and neck PET/CT, and contrast-enhanced CT in preoperative staging of clinically M0 squamous cell carcinoma of the head and neck.
    Rodrigues RS; Bozza FA; Christian PE; Hoffman JM; Butterfield RI; Christensen CR; Heilbrun M; Wiggins RH; Hunt JP; Bentz BG; Hitchcock YJ; Morton KA
    J Nucl Med; 2009 Aug; 50(8):1205-13. PubMed ID: 19617339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of Time-of-Flight PET/CT with a Large Axial Field of View for Reducing Whole-Body Acquisition Time.
    Akamatsu G; Uba K; Taniguchi T; Mitsumoto K; Narisue A; Tsutsui Y; Sasaki M
    J Nucl Med Technol; 2014 Jun; 42(2):101-4. PubMed ID: 24799607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.